Titlebook: Rare Lymphomas; Martin Dreyling,Michael E. Williams Book 2014 Springer-Verlag Berlin Heidelberg 2014 Malignant Lymphoma.Molecular Pathogen

變形詞

Principles of the Pathology and Biology of Malignant Lymphomas 1988) and the working formulation for clinical usage (WF; Non-Hodgkin’s lymphoma pathologic classification project 1982). Both classification systems relied upon entirely different principles. The Kiel classification was based on the exact morphological description and (later) immunological identif

follicle

coddle

Signaling Pathways in Rare Lymphomasys are equally of importance and discussed in the context of with mantle cell lymphoma and Burkitt’s lymphoma. A striking example of how dysregulation of immune surveillance pathways interfaces with activation of oncogenic pathways is seen in the case of primary mediastinal B-cell lymphoma.

stroke

頂點

Anaplastic Large Cell Lymphomand Drug Administration for this disease. Crizotinib, which targets the ALK kinase and has shown promising results in preclinical and a limited clinical setting, is currently being evaluated in phase II clinical studies. Future directions will aim at changing current treatment strategies by incorpora

大笑

Adrenal-Glands

Primary Mediastinal Large B-Cell Lymphomaximab reduced these differences and R-CHOP is now the most widely used treatment, as it is for other types of DLBCL. The role of consolidation with local radiotherapy, which is often used to treat residual mediastinal masses, still remains unclear. Treatment with R-CHOP followed by radiation therapy